|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNFRSF14 |
Gene summary for TNFRSF14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNFRSF14 | Gene ID | 8764 |
| Gene name | TNF receptor superfamily member 14 | |
| Gene Alias | ATAR | |
| Cytomap | 1p36.32 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A024R052 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8764 | TNFRSF14 | LZE4T | Human | Esophagus | ESCC | 1.30e-10 | 2.25e-01 | 0.0811 |
| 8764 | TNFRSF14 | LZE8T | Human | Esophagus | ESCC | 8.91e-12 | 3.24e-01 | 0.067 |
| 8764 | TNFRSF14 | LZE20T | Human | Esophagus | ESCC | 1.28e-05 | 3.26e-01 | 0.0662 |
| 8764 | TNFRSF14 | LZE22D1 | Human | Esophagus | HGIN | 4.94e-03 | 1.18e-01 | 0.0595 |
| 8764 | TNFRSF14 | LZE22T | Human | Esophagus | ESCC | 3.61e-03 | 1.32e-01 | 0.068 |
| 8764 | TNFRSF14 | LZE24T | Human | Esophagus | ESCC | 1.01e-12 | 4.09e-01 | 0.0596 |
| 8764 | TNFRSF14 | LZE6T | Human | Esophagus | ESCC | 2.02e-04 | 1.91e-01 | 0.0845 |
| 8764 | TNFRSF14 | P1T-E | Human | Esophagus | ESCC | 2.56e-04 | 4.21e-01 | 0.0875 |
| 8764 | TNFRSF14 | P2T-E | Human | Esophagus | ESCC | 4.53e-28 | 3.31e-01 | 0.1177 |
| 8764 | TNFRSF14 | P4T-E | Human | Esophagus | ESCC | 2.28e-11 | 2.84e-01 | 0.1323 |
| 8764 | TNFRSF14 | P5T-E | Human | Esophagus | ESCC | 1.36e-10 | 1.17e-01 | 0.1327 |
| 8764 | TNFRSF14 | P8T-E | Human | Esophagus | ESCC | 6.64e-45 | 9.33e-01 | 0.0889 |
| 8764 | TNFRSF14 | P9T-E | Human | Esophagus | ESCC | 6.55e-04 | 1.83e-01 | 0.1131 |
| 8764 | TNFRSF14 | P10T-E | Human | Esophagus | ESCC | 1.21e-07 | 2.22e-02 | 0.116 |
| 8764 | TNFRSF14 | P11T-E | Human | Esophagus | ESCC | 6.67e-10 | 4.77e-01 | 0.1426 |
| 8764 | TNFRSF14 | P12T-E | Human | Esophagus | ESCC | 2.88e-05 | 6.19e-02 | 0.1122 |
| 8764 | TNFRSF14 | P15T-E | Human | Esophagus | ESCC | 2.32e-07 | 2.56e-01 | 0.1149 |
| 8764 | TNFRSF14 | P16T-E | Human | Esophagus | ESCC | 1.81e-16 | 1.28e-01 | 0.1153 |
| 8764 | TNFRSF14 | P17T-E | Human | Esophagus | ESCC | 1.14e-08 | 4.40e-01 | 0.1278 |
| 8764 | TNFRSF14 | P20T-E | Human | Esophagus | ESCC | 9.66e-12 | 3.23e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
| GO:001905827 | Esophagus | HGIN | viral life cycle | 93/2587 | 317/18723 | 3.66e-13 | 5.63e-11 | 93 |
| GO:004440326 | Esophagus | HGIN | biological process involved in symbiotic interaction | 71/2587 | 290/18723 | 7.09e-07 | 3.00e-05 | 71 |
| GO:005170127 | Esophagus | HGIN | biological process involved in interaction with host | 51/2587 | 203/18723 | 1.16e-05 | 3.29e-04 | 51 |
| GO:005212627 | Esophagus | HGIN | movement in host environment | 43/2587 | 175/18723 | 9.45e-05 | 2.03e-03 | 43 |
| GO:003320910 | Esophagus | HGIN | tumor necrosis factor-mediated signaling pathway | 26/2587 | 99/18723 | 7.45e-04 | 9.90e-03 | 26 |
| GO:004440927 | Esophagus | HGIN | entry into host | 34/2587 | 151/18723 | 2.43e-03 | 2.43e-02 | 34 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:0051701111 | Esophagus | ESCC | biological process involved in interaction with host | 135/8552 | 203/18723 | 1.49e-09 | 3.49e-08 | 135 |
| GO:0052126111 | Esophagus | ESCC | movement in host environment | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:0044409111 | Esophagus | ESCC | entry into host | 96/8552 | 151/18723 | 6.73e-06 | 6.84e-05 | 96 |
| GO:003320914 | Esophagus | ESCC | tumor necrosis factor-mediated signaling pathway | 67/8552 | 99/18723 | 7.87e-06 | 7.72e-05 | 67 |
| GO:003461220 | Esophagus | ESCC | response to tumor necrosis factor | 149/8552 | 253/18723 | 1.47e-05 | 1.33e-04 | 149 |
| GO:004671827 | Esophagus | ESCC | viral entry into host cell | 89/8552 | 144/18723 | 6.84e-05 | 5.18e-04 | 89 |
| GO:007135620 | Esophagus | ESCC | cellular response to tumor necrosis factor | 132/8552 | 229/18723 | 1.69e-04 | 1.11e-03 | 132 |
| GO:00507775 | Esophagus | ESCC | negative regulation of immune response | 112/8552 | 194/18723 | 4.67e-04 | 2.62e-03 | 112 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Breast | DCIS |
| LTA | TNFRSF14 | LTA_TNFRSF14 | LT | Cervix | ADJ |
| BTLA | TNFRSF14 | BTLA_TNFRSF14 | BTLA | Cervix | ADJ |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Cervix | CC |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Cervix | Healthy |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Cervix | Precancer |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Endometrium | ADJ |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Endometrium | AEH |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Endometrium | Healthy |
| LTA | TNFRSF14 | LTA_TNFRSF14 | LT | Esophagus | ADJ |
| LTA | TNFRSF14 | LTA_TNFRSF14 | LT | Esophagus | ESCC |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Esophagus | ESCC |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | HNSCC | ADJ |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | HNSCC | OSCC |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Liver | Healthy |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Liver | Precancer |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Lung | AAH |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Prostate | BPH |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Prostate | Tumor |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Skin | cSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNFRSF14 | SNV | Missense_Mutation | c.583G>T | p.Gly195Trp | p.G195W | Q92956 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | |
| TNFRSF14 | SNV | Missense_Mutation | novel | c.531G>T | p.Glu177Asp | p.E177D | Q92956 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TNFRSF14 | SNV | Missense_Mutation | c.160N>C | p.Cys54Arg | p.C54R | Q92956 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
| TNFRSF14 | SNV | Missense_Mutation | rs371087831 | c.785C>T | p.Pro262Leu | p.P262L | Q92956 | protein_coding | deleterious(0.01) | possibly_damaging(0.818) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNFRSF14 | SNV | Missense_Mutation | c.558N>A | p.Ser186Arg | p.S186R | Q92956 | protein_coding | deleterious(0.03) | benign(0.3) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| TNFRSF14 | SNV | Missense_Mutation | c.823T>A | p.Ser275Thr | p.S275T | Q92956 | protein_coding | tolerated(0.76) | benign(0) | TCGA-QL-A97D-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TNFRSF14 | SNV | Missense_Mutation | c.779C>T | p.Ala260Val | p.A260V | Q92956 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-AF-A56N-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
| TNFRSF14 | SNV | Missense_Mutation | novel | c.631N>A | p.Val211Ile | p.V211I | Q92956 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNFRSF14 | SNV | Missense_Mutation | novel | c.454N>G | p.Lys152Glu | p.K152E | Q92956 | protein_coding | tolerated(1) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TNFRSF14 | SNV | Missense_Mutation | novel | c.644T>C | p.Val215Ala | p.V215A | Q92956 | protein_coding | tolerated(0.41) | benign(0.006) | TCGA-AP-A1DM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8764 | TNFRSF14 | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | 178101757 | |||
| 8764 | TNFRSF14 | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | 178101763 | |||
| 8764 | TNFRSF14 | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | 178101591 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |